• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, August 26, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Depleting CAR T cells after tumor treatment reverses B cell deficiency in mice

Bioengineer by Bioengineer
October 17, 2016
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Genetically engineered T cells, or CAR T cells, represent a promising approach to treat multiple types of cancer.

mice 7

These therapies can eliminate tumors by targeting specific markers that are expressed on different cancer cell types. CAR T cell treatments for B cell-associated cancers have been particularly successful in eradicating tumors. These treatments destroy tumor cells expressing CD19, a protein that is upregulated at the early stages of B cell development. Unfortunately, because CAR T cells persist after a patient goes into remission, continual targeting of CD19 can lead to long-term depletion of healthy B cells.

In this issue of the JCI, a team led by Dirk Busch at Technical University München has developed a strategy to prevent depletion of healthy B cells after successful CAR T cell treatments for B cell lymphomas. They created CD19-targeting CAR T cells that also express a non-functional form of another protein called EGFR. They then treated a mouse model of leukemia with the EGFR- and CD19-targeting T cells. After the treatment successfully eliminated B cell tumors in these mice, the researchers administered an antibody for EGFR, which depleted CAR T cells. This strategy permanently restored levels of healthy B cells without causing cancer relapse in the mouse model. This work provides evidence that incorporating an additional targeting mechanism into genetically engineered cells may improve the safety of these cell-based therapies.

###

TITLE:

Targeted antibody-mediated depletion of CD19 CAR-T cells permanently reverses B cell aplasia

AUTHOR CONTACT:

Dirk Busch
Technical University München
[email protected]

View this article at: http://www.jci.org/articles/view/84813?key=fed9e949b703c563bf23

Media Contact

Elyse Dankoski
[email protected]
@jclinicalinvest

http://www.jci.org

The post Depleting CAR T cells after tumor treatment reverses B cell deficiency in mice appeared first on Scienmag.

Share12Tweet8Share2ShareShareShare2

Related Posts

PON2: A Promising Biomarker and Cancer Therapy Target

August 25, 2025

Innovative Technique Investigates Cancer Cell Messengers That Suppress the Immune System

August 25, 2025

Vesalius Cell-Mapping Tool Offers In-Depth Multi-Layered Insights into Cancer Behavior

August 25, 2025

Scientists Develop Reliable Method to Measure Blood-Brain Barrier Opening with Focused Ultrasound

August 25, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    145 shares
    Share 58 Tweet 36
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Common Cold Could Offer Protection Against COVID-19, Finds National Jewish Health Study

Unraveling Ferroptosis in Esophageal Cancer Therapy

Impact of Iranian Medicinal Plants on Pancreatic Cancer

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.